ESMO 2020 – Andrés Cervantes

Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

Here is the full ESMO 2020 Solid Tumors report.

More posts

Ovarian cancer: taking PARP inhibition one step further

Niraparib has been approved as maintenance treatment for patients with plat­inum-sensitive recurrent ovarian cancer (OC) based on the results of the NOVA trial. The starting dose used in NOVA was 300 mg orally daily. A retrospective analysis indicated that individualized starting doses based on baseline body weight and platelet counts might improve the safety profile of niraparib without compromising efficacy.

Getting innovation from the laboratories into clinical practice

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Milestones of PD-1 inhibition in gastric and esophageal cancer

Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma are substantial causes of cancer-related mortality worldwide and have poor 5-year overall survival (OS) when diagnosed at an advanced stage. Median OS with standard first-line chemotherapy for advanced or metastatic, HER2-negative gastric and GEJ cancer is less than 1 year.